This rare heart condition is fatal without intervention - and the only treatment that can save this boy now must happen abroad, at a cost his mother cannot afford ...

This weekend marks the start of Congenital Heart Defect Awareness Week, a time to highlight a condition that affects about one in 100 babies during pregnancy and can change families’ lives forever.

Pivotal Phase 2b clinical trial (ELPIS II) for Lomecel-B™ has achieved over 90% enrollment and is expected to complete enrollment by Q2 2025, indicating strong progress in a rare pediatric disease ...

Born with a rare heart defect, Dylan survived 3 surgeries and now raises awareness as a Kids Heart ambassador, inspiring ...

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical ...